HOME >> BIOLOGY >> NEWS
'Quiet revolution' may herald new RNA therapeutics

Scientists at the University of Oxford have identified a surprising way of switching off a gene involved in cell division. The mechanism involves a form of RNA, a chemical found in cell nuclei, whose role was previously unknown, and could have implications for preventing the growth of tumour cells.

RNA plays an important and direct role in the synthesis of proteins, the building blocks of our bodies. However, scientists have known for some time that not all types of RNA are directly involved in protein synthesis. Now, in research funded by the Wellcome Trust and the Medical Research Council, a team of scientists has shown that one particular type of RNA plays a key role in regulating the gene implicated in control of tumour growth. The research is published online today in Nature.

The Human Genome Project identified about 34,000 genes responsible for producing proteins. The remaining part in fact, most of the genome constituted what was considered to be "junk" DNA with no function. However, latest estimates show that this "junk" DNA produces around half a million varieties of RNA of unknown functions.

"There's been a quiet revolution taking place in biology during the past few years over the role of RNA," says Dr Alexandre Akoulitchev, a Senior Research Fellow at the University of Oxford. "Scientists have begun to see 'junk' DNA as having a very important function. The variety of RNA types produced from this "junk" is staggering and the functional implications are huge."

The particular form of RNA that has been of interest to Dr Akoulitchev's team is involved in regulation of the dihydrofolate reductase gene (DHFR), determining whether the gene is "on" or "off". The DHFR gene produces an enzyme that controls thymine production, necessary in rapidly dividing cells.

"Inhibiting the DHFR gene could help prevent the growth of neoplastic cancerous cells, ordinary cells which develop into tumour cells, such as in pro
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
21-Jan-2007


Page: 1 2

Related biology news :

1. Northeast Sun Grant Institute at Cornell spurs green revolution
2. Emerging research heralds new era of breast cancer management
3. Gene breakthrough heralds better prospect for malaria solution
4. VBI research offers potential route to diabetes therapeutics
5. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
6. Recycled or revamped therapeutics find novel anti-cancer applications
7. Study reveals candidate targets for anti-retroviral therapeutics
8. New protein structure may aid in design of therapeutics for autoimmune disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Quiet revolution may herald new RNA therapeutics

(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
Cached News: